Penn Medicine Provider
Pathology and Laboratory Medicine
MacLean Nasrallah, MD, PhD
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP

About me

  • Assistant Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania

My clinical expertise is in neuropathology and molecular pathology of neuropathology.

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Hospital of the University of Pennsylvania

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Nasrallah is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Viaene AN, Santi M, Rosenbaum J, Li MM, Surrey LF, Nasrallah MP SETD2 mutations in primary central nervous system tumors , Acta Neuropathol Commun, 6(1): 2018,123


Bagley SJ, Schwab RD, Nelson E, Viaene AN, Binder ZA, Lustig RA, O'Rourke DM, Brem S, Desai AS, Nasrallah MP Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma , J Neurooncology, 141(2): 2019,421-429


Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O'Rourke DM Epidermal growth factor receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development , Cancer Cell, 34(1): 2018,163-177


Akbari H, Bakas S, Pisapia JM, Nasrallah MP, Rozycki M, Martinez-Lage M, Morrissette JJD, Dahmane N, O'Rourke DM, Davatzikos C In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature , Neuro Oncol, 20(8): 2018,1068-1079


Rathore S, Akbari H, Rozycki M, Abdullah KG, Nasrallah MP, Binder ZA, Davuluri RV, Lustig RA, Dahmane N, Bilello M, O'Rourke DM, Davatzikos C Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1. , Sci Rep, 8(1): 2018,5087


O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , Sci Transl Med, 9(399): 2017,399


Zeh R, Sheikh S, Xia L, Pierce J, Newton A, Predina J, Cho S, Nasrallah M, Singhal S, Dorsey J, Lee JYK The second window ICG technique demonstrates a broad plateau period for near infrared fluorescence tumor contrast in glioblastoma , PLoS One, 12(7): 2017,e0182034


Pierce JT, Cho SS, Nag S, Zeh R, Jeon J, Holt D, Durham A, Nasrallah MP, Singhal S, Lee JYK Folate receptor overexpression in human and canine meningiomas-immunohistochemistry and case report of intraoperative molecular imaging , Neurosurgery, 85(3): 2019,359-368


Henrickson SE, Walter JE, Quinn C, Kanakry JA, Bardakjian T, Dimitrova D, Ujhazi B, Csomos K, Bosticardo M, Dobbs K, Nasrallah M, Notarangelo LD, Holland SM, Fadugba O Adult-Onset Myopathy in a Patient with Hypomorphic RAG2 Mutations and Combined Immune Deficiency , J Clin Immunol, 38(6): 2018,642–645


McManus MF, Nasrallah IM, Pancoast MM, Wynshaw-Boris A, Golden JA Lis1 is necessary for normal non-radial migration of inhibitory interneurons , Am J Pathol, 165(3): 2004,775-84


View all publications